Q-omics provides the consensus-scored STX16 profile across patient tissues and cancer cell-line models. STX16 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STX16 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, STX16 protein abundance shows 21,685 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where STX16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STX16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STX16 survival associations across molecular data types. STX16 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STX16 RNA expression–survival associations across cancer types. High STX16 expression shows unfavorable associations in KIRC, LIHC, LGG, ACC and COAD, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STX16 RNA expression.
This table summarizes STX16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for STX16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STX16 shows higher tumor expression in HNSC, KIRC, COAD, LIHC, STAD and KIRP. The HNSC box plot shows higher STX16 RNA expression in tumor versus normal tissue (log2 FC = +0.923, t-test p < 0.001).
This table shows molecular features associated with STX16 in patient tissues and cancer cell lines. In patient samples, STX16 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, STX16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
